Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1978;5(Suppl 1):21S–28S.

Cardiovascular responses to mianserin hydrochloride

A comparison with tricyclic antidepressant drugs

C D Burgess, P Turner, Jane Wadsworth
PMCID: PMC1429203  PMID: 341940

Abstract

1 The cardiovascular responses of mianserin hydrochloride and tricyclic antidepressant drugs were investigated using non-invasive methods of cardiac investigation. A study of the interaction of mianserin and antihypertensive drug therapy is reported.

2 In six normal volunteers, mianserin hydrochloride 20 mg was shown to prolong the corrected Q-T interval at 150 min (P<0.001). It did not affect heart rate, systolic time intervals or the peak normalized derivative of the apexcardiogram. Amitriptyline 50 mg increased the corrected pre-ejection period interval (PEPI) and the PEP/left ventricular ejection time (LVET) ratio of the systolic time intervals at 150 min (P<0.001). Q-T interval was shortened at 90 minutes.

3 In a double-blind patient study, clomipramine increased heart rate, P-R interval, QRS and corrected Q-T interval in one patient at 2 weeks. Mianserin prolonged corrected Q-T interval at 1 week but this returned to the pretreatment time by 2 weeks in two patients.

4 In an open study, mianserin 20 mg three times daily did not antagonize the hypotensive action of propranolol or propranolol and hydrallazine in three patients.

5 In a double-blind study in three patients with desmethylimipramine 25 mg three times daily, mianserin 20 mg three times daily did not antagonize the hypotensive action of either guanethidine or bethanidine.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bigger J. T., Giardina E. G., Perel J. M., Kantor S. J., Glassman A. H. Cardiac antiarrhythmic effect of imipramine hydrochloride. N Engl J Med. 1977 Jan 27;296(4):206–208. doi: 10.1056/NEJM197701272960407. [DOI] [PubMed] [Google Scholar]
  2. Briant R. H., Reid J. L., Dollery C. T. Interaction between clonidine and desipramine in man. Br Med J. 1973 Mar 3;1(5852):522–523. doi: 10.1136/bmj.1.5852.522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burrows G. D., Vohra J., Hunt D., Sloman J. G., Scoggins B. A., Davies B. Cardiac effects of different tricyclic antidepressant drugs. Br J Psychiatry. 1976 Oct;129:335–341. doi: 10.1192/bjp.129.4.335. [DOI] [PubMed] [Google Scholar]
  4. Coppen A., Gupta R., Montgomery S., Ghose K., Bailey J., Burns B., de Ridder J. J. Mianserin hydrochloride: a novel antidepressant. Br J Psychiatry. 1976 Oct;129:342–345. doi: 10.1192/bjp.129.4.342. [DOI] [PubMed] [Google Scholar]
  5. Coull D. C., Crooks J., Dingwall-Fordyce I., Scott A. M., Wier R. D. Amitriptyline and cardiac disease. Risk of sudden death identified by monitoring system. Lancet. 1970 Sep 19;2(7673):590–591. doi: 10.1016/s0140-6736(70)90169-8. [DOI] [PubMed] [Google Scholar]
  6. Crome P., Newman B. Poisoning with maprotiline and mianserin. Br Med J. 1977 Jul 23;2(6081):260–260. doi: 10.1136/bmj.2.6081.260-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dauchot P., Gravenstein J. S. Effects of atropine on the electrocardiogram in different age groups. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):274–280. doi: 10.1002/cpt1971122part1274. [DOI] [PubMed] [Google Scholar]
  8. Denef B., Popeye R., Geest H. D., Kesteloot H. On the clinical value of calibrated displacement apexcardiography. Circulation. 1975 Mar;51(3):541–551. doi: 10.1161/01.cir.51.3.541. [DOI] [PubMed] [Google Scholar]
  9. Ghose K., Coppen A., Turner P. Autonomic actions and interactions of mianserin hydrochloride (Org. GB 94) and amitriptyline in patients with depressive illness. Psychopharmacology (Berl) 1976 Sep 17;49(2):201–204. doi: 10.1007/BF00427291. [DOI] [PubMed] [Google Scholar]
  10. Gravenstein J. S., Ariet M., Thornby J. I. Atropine on the electrocardiogram. Clin Pharmacol Ther. 1969 Sep-Oct;10(5):660–666. doi: 10.1002/cpt1969105660. [DOI] [PubMed] [Google Scholar]
  11. Hayes J. R., Born G. F., Rosenbaum A. H. Incidence of orthostatic hypotension in patients with primary affective disorders treated with tricyclic antidepressants. Mayo Clin Proc. 1977 Aug;52(8):509–512. [PubMed] [Google Scholar]
  12. James T. N., Isobe J. H., Urthaler F. Analysis of components in a cardiogenic hypertensive chemoreflex. Circulation. 1975 Aug;52(2):179–192. doi: 10.1161/01.cir.52.2.179. [DOI] [PubMed] [Google Scholar]
  13. Jefferson J. W. A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosom Med. 1975 Mar-Apr;37(2):160–179. doi: 10.1097/00006842-197503000-00006. [DOI] [PubMed] [Google Scholar]
  14. KRISTIANSEN E. S. Cardiac complications during treatment with imipramin (Tofranil). Acta Psychiatr Scand. 1961;36:427–442. doi: 10.1111/j.1600-0447.1961.tb01057.x. [DOI] [PubMed] [Google Scholar]
  15. Meyer J. F., McAllister C. K., Goldberg L. I. Insidious and prolonged antagonism of guanethidine by amitriptyline. JAMA. 1970 Aug 31;213(9):1487–1488. [PubMed] [Google Scholar]
  16. Mitchell J. R., Cavanaugh J. H., Arias L., Oates J. A. Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970 Aug;49(8):1596–1604. doi: 10.1172/JCI106377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Moir D. C., Cornwell W. B., Dingwall-Fordyce I., Crooks J., O'Malley K., Turnbull M. J., Weir R. D. Cardiotoxicity of amitriptyline. Lancet. 1972 Sep 16;2(7777):561–564. doi: 10.1016/s0140-6736(72)91958-7. [DOI] [PubMed] [Google Scholar]
  18. Morgan P. H., Mathison I. W. Arrhythmias and antiarrhythmic drugs: mechanism of action and structure-activity relationships II. J Pharm Sci. 1976 May;65(5):635–648. doi: 10.1002/jps.2600650503. [DOI] [PubMed] [Google Scholar]
  19. Müller V., Burckhardt D. Die Wirkung tri- und tetrazyklischer Antidepressiva auf Herz und Kreislauf. Schweiz Med Wochenschr. 1974 Dec 21;104(51):1911–1913. [PubMed] [Google Scholar]
  20. RASMUSSEN E. B., KRISTJANSEN P. ECG changes during amitryptiline treatment. Am J Psychiatry. 1963 Feb;119:781–782. doi: 10.1176/ajp.119.8.781. [DOI] [PubMed] [Google Scholar]
  21. Singh B. N., Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J. 1974 Mar;87(3):367–382. doi: 10.1016/0002-8703(74)90080-5. [DOI] [PubMed] [Google Scholar]
  22. Skinner C., Coull D. C., Johnston A. W. Antagonism of the hypotensive action of bethanidine and debrisoquine by tricyclic antidepressants. Lancet. 1969 Sep 13;2(7620):564–566. doi: 10.1016/s0140-6736(69)90262-1. [DOI] [PubMed] [Google Scholar]
  23. Thorstrand C. Cardiovascular effects of poisoning with tricyclic antidepressants. Acta Med Scand. 1974 Jun;195(6):505–514. doi: 10.1111/j.0954-6820.1974.tb08179.x. [DOI] [PubMed] [Google Scholar]
  24. Thorstrand C. Clinical features in poisonings by tricyclic antidepressants with special reference to the ECG. Acta Med Scand. 1976;199(5):337–344. doi: 10.1111/j.0954-6820.1976.tb06745.x. [DOI] [PubMed] [Google Scholar]
  25. Vohra J., Burrows G. D., Sloman G. Assessment of cardiovascular side effects of therapeutic doses of tricyclic anti-depressant drugs. Aust N Z J Med. 1975 Feb;5(1):7–11. doi: 10.1111/j.1445-5994.1975.tb03247.x. [DOI] [PubMed] [Google Scholar]
  26. WHITE A. G. METHYLDOPA AND AMITRIPTYLINE. Lancet. 1965 Aug 28;2(7409):441–441. doi: 10.1016/s0140-6736(65)90792-0. [DOI] [PubMed] [Google Scholar]
  27. Weissler A. M. Current concepts in cardiology. Systolic-time intervals. N Engl J Med. 1977 Feb 10;296(6):321–324. doi: 10.1056/NEJM197702102960607. [DOI] [PubMed] [Google Scholar]
  28. Weissler A. M., Harris W. S., Schoenfeld C. D. Bedside technics for the evaluation of ventricular function in man. Am J Cardiol. 1969 Apr;23(4):577–583. doi: 10.1016/0002-9149(69)90012-5. [DOI] [PubMed] [Google Scholar]
  29. Ziegler V. E., Co B. T., Biggs J. T. Plasma nortriptyline levels and ECG findings. Am J Psychiatry. 1977 Apr;134(4):441–443. doi: 10.1176/ajp.134.4.441. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES